Reference
Sun X, et al. Cost-utility analysis of imrecoxib compared with diclofenac for patients with osteoarthritis. Cost Effectiveness and Resource Allocation : 20 Apr 2021. Available from: URL: https://doi.org/10.1186/s12962-021-00275-7
Rights and permissions
About this article
Cite this article
Imrecoxib "valuable treatment option" for patients with osteoarthritis in China. PharmacoEcon Outcomes News 877, 9 (2021). https://doi.org/10.1007/s40274-021-7658-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-021-7658-3